zintick
CLYM Climb Bio-13.5%Stock moveFDA and trials

Climb Bio Stock Falls 13.5% on the Day It Reported Early Kidney Drug Data

The filing, accepted before the open Monday, reported initial Phase 2 results for budoprutug in primary membranous nephropathy, and no source ties the decline to a specific item in it.

By Zintick Team · Editor: Kratik Mehta
Published

Covid 19 corona virus vaccine vial bottles for intramuscular injections on medical pharmaceutical industry background. Corona
Photo: Ground Picture/Shutterstock.com

Key points

  • Shares fell 13.5% Monday, closing at $8.81 from $10.19, on volume 3.5 times normal; the S&P 500 ETF rose 0.71%
  • The day's news was an 8-K accepted at 6:24 a.m. Eastern with initial PrisMN Phase 2 data for budoprutug in membranous nephropathy
  • 200 mg cohort: 70% mean PLA2R antibody reduction at Week 12; 5 of 13 patients (38%) reached immunologic remission
  • Cash of $44.1 million at June 30, 2026; quarterly net loss of $13.5 million, wider than $8.7 million a year earlier

Climb Bio (Nasdaq: CLYM) shares fell 13.5% on Monday, Oct. 26, closing at $8.81 from a previous close of $10.19, while the S&P 500 ETF (SPY) rose 0.71%. Volume was 3.5 times normal. The decline came on the day the company filed an 8-K accepted at 6:24 a.m. Eastern, which reported initial Phase 2 data for budoprutug, its anti-CD19 antibody, in primary membranous nephropathy. No source ties the decline to a specific item in that filing.

What the PrisMN filing reported

At Week 12, the 200 mg cohort of the PrisMN trial showed B-cell depletion, a mean 70% reduction in PLA2R antibody levels, and immunologic remission in five of 13 patients (38%). Patients with baseline PLA2R antibody levels below 175 RU/mL had a mean reduction of 80%. The company said the 200 mg results were consistent with its Phase 1b Week 12 data. The filing also described the ongoing 600 mg cohort, where mean peripheral CD20+ B-cell suppression at Week 4 was 98%, compared with 74% at 200 mg. The 1000 mg cohort is still enrolling.

Cash and losses in context

Climb Bio had $44.1 million in cash and equivalents as of June 30, 2026. Its net loss for the quarter ended that day was $13.5 million, compared with $8.7 million a year earlier, a wider loss. Operating loss for the quarter was $15.4 million, against $10.7 million a year earlier. The company's corporate presentation says its cash runway extends into the second half of 2028. Before the move, the company's market value was about $585 million.

Earlier filing that week

On Oct. 23, the company filed a separate 8-K reporting additional Phase 1 data for CLYM116, its anti-APRIL antibody being developed for IgA nephropathy with partner Beijing Mabworks. That filing said initial NAVIGATE-2 Phase 2 data remain expected in the first half of 2027.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

CLYM page →

Filings, figures and price history are on the Climb Bio page.